AC
ALGS icon

Armistice Capital’s Aligos Therapeutics ALGS Stock Holding History

Armistice Capital’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-315,095
Closed -$2.73M – 235
2024
Q3 		$2.73M Buy
315,095
+24,839
+9% +$309K 0.04% 149
2024
Q2 		$2.54M Buy
290,256
+14,520
+5% +$255K 0.03% 141
2024
Q1 		$6.76M Buy
275,736
+2,381
+0.9% +$47.4K 0.09% 112
2023
Q4 		$4.54M Buy
+273,355
New +$4.7M 0.06% 126

Other funds holding ALGS

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TI
Trexquant Investment Stamford, Connecticut $17B AUM 39.66% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Armistice Capital's ALGS Position: Q4 2024 in Review

Armistice Capital sold out of Aligos Therapeutics (ALGS) in Q4 2024, closing a stake of 315,095 shares — an estimated $2.73M sold.

Armistice Capital first reported a position in ALGS in Q4 2023 and held it in 4 quarters. The position peaked at $6.76M in Q1 2024. 34 funds tracked by Wall St. Rank hold ALGS as of Q4 2024.

  • Armistice Capital reported no remaining Aligos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Armistice Capital sold 315,095 Aligos Therapeutics shares in Q4 2024, an estimated $2.73M.
  • Armistice Capital first reported a position in Aligos Therapeutics in Q4 2023 and held it in 4 quarters.
  • Armistice Capital's Aligos Therapeutics position peaked at $6.76M in Q1 2024.
  • 34 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2024.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.